Clinical trialNCT04616924TerminatedPhase 3Interventional

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

SponsorRedHill Biopharma LimitedEnrollment12BronchiectasisLung DiseasesPulmonary Mycobacterium Avium Complex Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung infection.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

June L Almenoff, MD, PhD
RedHill Biopharma, Inc.
Study Chair
clinicaltrials.gov ↗
Kevin L. Winthrop, MD, MPH
Oregon Health and Science University
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Medical Facility
Glendale, California, United States
Medical Facility
Palm Springs, California, United States
Medical Facility
Farmington, Connecticut, United States
Medical Facility
Washington D.C., District of Columbia, United States
Medical Facility
Clearwater, Florida, United States
Medical Facility
Gainesville, Florida, United States
Medical Facility
Margate, Florida, United States
Medical Facility 1
Orlando, Florida, United States
Medical Facility 2
Orlando, Florida, United States
Medical Facility
Sebring, Florida, United States
Medical Facility
Vero Beach, Florida, United States
Medical Facility
Atlanta, Georgia, United States
Medical Facility
Valdosta, Georgia, United States
Medical Facility
Kansas City, Kansas, United States
Medical Facility
New Orleans, Louisiana, United States
Medical Facility
Boston, Massachusetts, United States
Medical Facility
Rochester, Minnesota, United States
Medical Facility
St Louis, Missouri, United States
Medical Facility
Newark, New Jersey, United States
Medical Facility
New York, New York, United States
Medical Facility
Winston-Salem, North Carolina, United States
Medical Facility
Portland, Oregon, United States
Medical Facility
Charleston, South Carolina, United States
Medical Facility
Tyler, Texas, United States
Medical Facility
Wauwatosa, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboRHB-204

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Dec 2020
Primary completion: 28 Aug 2023
Completion: 28 Aug 2023
Last update posted: 18 Mar 2025
Registered enrollment: 12
Registry id: NCT04616924

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.